Barclays analyst Tom O’Malley maintains Veeco Instruments (NASDAQ:VECO) with a Overweight and lowers the price target from $26 to $24.
Protagonist Therapeutics Reports Resolution Of Contract Dispute With Zealand Pharma; Protagonist To Make $1.5M Payment To Zealand
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future development and